Pfizer Inc. is poised to release its highly anticipated second-quarter 2025 earnings data, with financial analysts closely monitoring the biopharmaceutical giant’s performance. The market eagerly awaits the report, scheduled for release before trading commences on Tuesday, August 5th, to gauge the company’s financial health and future trajectory.
Expert projections indicate that Pfizer is expected to announce earnings per share (EPS) of $0.57 for the quarter, alongside an estimated revenue of $13.43 billion. These figures are crucial for investors and market watchers as they provide key insights into the company’s operational efficiency and market demand for its diverse product portfolio.
Recent stock performance for Pfizer (NYSE:PFE) shows shares opening at $23.49 on Friday. Over the past 52 weeks, the stock has experienced fluctuations, reaching a low of $20.92 and a high of $31.32, reflecting the inherent volatility within the pharmaceutical industry and broader market conditions.
Delving into Pfizer’s core financial metrics reveals a robust market capitalization of $133.55 billion. The company currently holds a price-to-earnings (P/E) ratio of 17.02, a price-to-earnings-growth (PEG) ratio of 0.85, and a beta of 0.52, suggesting a relatively stable investment compared to the overall market. These metrics are vital for investors conducting stock market analysis.
Further examination of Pfizer’s financial standing shows a 50-day moving average of $24.36 and a 200-day moving average of $24.57, indicating recent price trends. The company also maintains a quick ratio of 0.96, a current ratio of 1.26, and a debt-to-equity ratio of 0.64, collectively pointing to sound liquidity and manageable leverage.
In a recent development significant for shareholders, Pfizer announced a quarterly dividend of $0.43 per share, payable on Tuesday, September 2nd. Shareholders recorded as of Friday, July 25th, will be eligible for this distribution, which represents a $1.72 annualized dividend and an attractive yield of 7.3%. The ex-dividend date was Friday, July 25th, with a dividend payout ratio (DPR) of 124.64%.
Institutional investor interest in Pfizer remains strong, with Revolve Wealth Partners LLC notably increasing its position in the company by 12.5% during the fourth quarter, as detailed in its latest 13F filing with the Securities and Exchange Commission (SEC). The fund now holds 18,766 shares of Pfizer stock, valued at $498,000, underscoring significant institutional confidence, with 68.36% of the stock owned by such entities.
Globally, Pfizer Inc. operates as a leading biopharmaceutical company, engaged in the discovery, development, manufacturing, marketing, and distribution of a wide array of pharmaceutical products. Its diverse portfolio spans critical therapeutic areas, including cardiovascular metabolic, migraine, women’s health, infectious diseases, and COVID-19 prevention and treatment, marketed under well-known brands like Eliquis, Prevnar family, Comirnaty, and Paxlovid.
